Pulmonary Hypertension

Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study - Diagnostic and Interventional Cardiology Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study - Diagnostic and Interventional Cardiology Posted: 27 Feb 2020 11:43 AM PST February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study in the United States for an implantable device to treat pulmonary arterial hypertension (PAH).  The funding will support an U.S. Food and Drug Administration (FDA) early feasibility investigational study designed to evaluate long term implants of the Aria CV Pulmonary Hypertension System (Aria CV PH System) in PAH patients. The Series B funding close comes just one week after the Aria CV PH System was granted Breakthrough Device Designation by the FDA , which is intended to expedite the FDA review and approval of designated devices that may provide more effective ...

Sanofi To Pay $12M To End Mass. Medicare Kickback Probe - Law360 Sanofi To Pay $12M To End Mass. Medicare Kickback Probe - Law360 Posted: 28 Feb 2020 04:36 PM PST Law360 (February 28, 2020, 7:36 PM EST) -- Sanofi-Aventis U.S. LLC has agreed to pay $11.85 million to resolve allegations that it violated the False Claims Act by paying kickbacks to Medicare patients through a charity, the Boston U.S. attorney's office announced Friday in the latest settlement over similar allegations. According to the government's allegations, Sanofi funneled money to a charity called The Assistance Fund. The payments were not donations, but were instead a means to help pay copays for patients taking Lemtrada, Sanofi's multiple sclerosis drug that costs nearly $100,000 per patient per year, the government claimed. "Sanofi used a supposed charity as a conduit to funnel money... You are subscribed to email updates from "pulmonar...

My Rare Disease Intensifies My Emotions - Pulmonary Hypertension News My Rare Disease Intensifies My Emotions - Pulmonary Hypertension News Posted: 28 Feb 2020 07:00 AM PST Sometimes I think my emotions are too much to handle. I find myself wondering if I am overreacting or feeling things too strongly. However, c hronic illness has taught me that I need to feel my emotions. I can't bottle them up, hide them from the world, or numb myself. Hiding from my emotions brought me confusion, anxiety, and depression . For a long time, I felt as though my mind controlled me. It felt frightening and isolating. My emotions were a source of shame until I realized the power that comes from releasing them. I had no outlet to express myself w hen I  disguised my true feelings with a smile. I felt I would lose myself without my "bubbly" and "bright" side. My rare disease opened my eyes to how...

Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study - Diagnostic and Interventional Cardiology Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study - Diagnostic and Interventional Cardiology Posted: 27 Feb 2020 11:43 AM PST February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study in the United States for an implantable device to treat pulmonary arterial hypertension (PAH).  The funding will support an U.S. Food and Drug Administration (FDA) early feasibility investigational study designed to evaluate long term implants of the Aria CV Pulmonary Hypertension System (Aria CV PH System) in PAH patients. The Series B funding close comes just one week after the Aria CV PH System was granted Breakthrough Device Designation by the FDA , which is intended to expedite the FDA review and approval of designated devices that may provide more effective ...

Inhalation Therapy Shows Promise Against Pulmonary Fibrosis in Mice, Rats - NC State News Inhalation Therapy Shows Promise Against Pulmonary Fibrosis in Mice, Rats - NC State News Posted: 28 Feb 2020 02:02 AM PST A new study from North Carolina State University shows that lung stem cell secretions – specifically exosomes and secretomes – delivered via nebulizer, can help repair lung injuries due to multiple types of pulmonary fibrosis in mice and rats. The work could lead to more effective, less invasive treatment for human pulmonary fibrosis sufferers. Pulmonary fibrosis is a fatal disease that thickens and scars healthy lung tissue, creating inflammation and replacing the lining of the lung cells with fibrotic tissue. In the last five years, Ke Cheng and his lab developed spheroid-produced lung stem cells (LSCs) as a potential therapeutic for pulmonary fibrosis. Cheng is the Randall B. Terry Jr. Distinguished Professor in Regenerative...

Women Patients Still Missing in Heart Research | Health News - U.S. News & World Report Women Patients Still Missing in Heart Research | Health News - U.S. News & World Report Posted: 18 Feb 2020 12:00 AM PST [unable to retrieve full-text content] Women Patients Still Missing in Heart Research | Health News    U.S. News & World Report You are subscribed to email updates from "pulmonary hypertension prognosis" - Google News . To stop receiving these emails, you may unsubscribe now . Email delivery powered by Google Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States

Specific gut bacteria may be associated with pulmonary arterial hypertension - Science Daily Specific gut bacteria may be associated with pulmonary arterial hypertension - Science Daily Posted: 24 Feb 2020 04:54 AM PST Researchers have identified a distinct collection of bacteria found in the gut that may contribute to and predict the development of pulmonary arterial hypertension (PAH), according to new research published today in the American Heart Association's journal Hypertension . PAH is a chronic and progressive disease in which the arteries that supply blood to the lungs are constricted, resulting in symptoms such as shortness of breath, heart palpitations, fatigue and others. In PAH, persistently high blood pressure in lung arteries makes the right side of the heart work too hard to pump blood, resulting in right-sided heart failure (inability of the heart to pump blood adequately). It is much less common than systemic blood pre...